Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 18/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.51 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.51 |
| ▸ | CYP11A1 | P05108 | 1/20 | 0.51 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.51 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.51 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.51 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.51 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phenglutarimide SCHEMBL1649930 | 0.97 | CYP19A1 (0.56) | CYP19A1ALDH1A1CYP1A2CYP2D6 | |
| Glutethimide SCHEMBL113709 | 0.82 | CYP19A1 (0.72) | CYP19A1ALDH1A1CYP1A2CYP2D6CYP3A4 | |
| Glutethimide SCHEMBL21119240 | 0.82 | CYP19A1 (0.72) | CYP19A1ALDH1A1CYP1A2CYP2D6CYP3A4 | |
| Glutethimide SCHEMBL113708 | 0.82 | CYP19A1 (0.72) | CYP19A1ALDH1A1CYP1A2CYP2D6CYP3A4 | |
| SCHEMBL11847657 | 0.77 | ALDH1A1 (0.54) | CYP19A1ALDH1A1CYP1A2CYP2D6 | |
| Glutethimide SCHEMBL28781825 | 0.76 | CYP19A1 (0.63) | CYP19A1ALDH1A1CYP1A2CYP2D6CYP3A4 | |
| SCHEMBL17471628 | 0.76 | CYP19A1 (0.53) | CYP19A1ALDH1A1 | |
| SCHEMBL6246501 | 0.75 | CYP19A1 (0.52) | CYP19A1ALDH1A1CYP1A2CYP2D6CYP3A4 | |
| Hydrochloric Acid SCHEMBL10920499 | 0.75 | SIGMAR1 (0.43) | ALDH1A1 | |
| SCHEMBL11929003 | 0.74 | SIGMAR1 (0.40) | ALDH1A1CYP1A2CYP2D6CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 385 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4154879-B1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING NICOTINE WITHDRAWAL SYMPTOMS | KOREA INST SCI & TECH (KR) | 2025-09-10 | — | — | EP | claimed |
| WO-2025038382-A1 | PHARMACEUTICAL ADHESIVE COMPOSITIONS | MOMENTIVE PERFORMANCE MATERIALS INC. (US) | 2025-02-20 | — | — | WO | claimed |
| WO-2024218296-A1 | COMBINATION TREATMENTS COMPRISING ADMINISTRATION OF LEUCINE-RICH REPEAT KINASE 2 (LRRK2) INHIBITORS | H. LUNDBECK A/S (DK) | 2024-10-24 | — | — | WO | claimed |
| EP-4154879-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING NICOTINE WITHDRAWAL SYMPTOMS | Korea Institute of Science and Technology (KR) | 2023-03-29 | — | — | EP | claimed |
| EP-3852608-A1 | COMPOSITIONS AND METHODS FOR GLAUCOMA | Aufbau Medical Innovations Limited (IE) | 2021-07-28 | — | — | EP | claimed |
| US-10987316-B2 | Compositions and methods for transdermal delivery of tertiary amine drugs | NOVEN PHARMACEUTICALS, INC. (US) | 2021-04-27 | — | — | US | claimed |
| WO-2020061550-A1 | COMPOSITIONS AND METHODS FOR GLAUCOMA | AUFBAU MEDICAL INNOVATIONS LIMITED (IE) | 2020-03-26 | — | — | WO | claimed |
| US-10406116-B2 | Pressure-sensitive adhesives for transdermal drug delivery | NOVEN PHARMACEUTICALS, INC. (US) | 2019-09-10 | — | — | US | claimed |
| EP-3506889-A1 | PRESSURE-SENSITIVE ADHESIVES FOR TRANSDERMAL DRUG DELIVERY | Noven Pharmaceuticals, INC. (US) | 2019-07-10 | — | — | EP | claimed |
| WO-2018026759-A1 | PRESSURE-SENSITIVE ADHESIVES FOR TRANSDERMAL DRUG DELIVERY | NOVEN PHARMACEUTICALS, INC. (US) | 2018-02-08 | — | — | WO | claimed |
| EP-1829527-A2 | Aggregate with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin | IDEA AG (DE) | 2007-09-05 | — | — | EP | claimed |
| EP-1815846-A2 | Aggregate with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin | IDEA AG (DE) | 2007-08-08 | — | — | EP | claimed |
| EP-1815847-A2 | Aggregate with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin | IDEA AG (DE) | 2007-08-08 | — | — | EP | claimed |
| CN-1703199-A | Aggregate with enhanced deformability comprising at least three amphiphiles for improved transport through a semi-permeable barrier and use of non-invasive drugs in vivo, in particular through the skin | IDEA AG (DE) | 2005-11-30 | — | — | CN | claimed |
| EP-1551370-A1 | AGGREGATE WITH INCREASED DEFORMABILITY, COMPRISING AT LEAST THREE AMPHIPATS, FOR IMPROVED TRANSPORT THROUGH SEMI-PERMEABLE BARRIERS AND FOR THE NON-INVASIVE DRUG APPLICATION IN VIVO, ESPECIALLY THROUGH THE SKIN | IDEA AG (DE) | 2005-07-13 | — | — | EP | claimed |
| US-20040105881-A1 | Aggregates with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin | IDEA AG (DE) | 2004-06-03 | — | — | US | claimed |
| WO-2004032900-A1 | AGGREGATE WITH INCREASED DEFORMABILITY, COMPRISING AT LEAST THREE AMPHIPATS, FOR IMPROVED TRANSPORT THROUGH SEMI-PERMEABLE BARRIERS AND FOR THE NON-INVASIVE DRUG APPLICATION IN VIVO, ESPECIALLY THROUGH THE SKIN | IDEA AG (DE) | 2004-04-22 | — | — | WO | claimed |
| CN-1294519-A | Pharmaceutical composition containing a compound having an activity of promoting the absorption of an active ingredient | INPHARMA SA (CH) | 2001-05-09 | — | — | CN | claimed |
| EP-1073470-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2001-02-07 | — | — | EP | claimed |
| WO-2000048636-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2000-08-24 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040105881-A1 | Aggregates with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin | CUTA, ABCG2, PIGS | CYP19A1 3028/4885ALDH1A1 2042/4885CYP1A2 1571/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.